Intraday slump: TripSitter Clinic Ltd. (KETA.CN CNQ) falls -88.78% on 13 Feb 2026 : what investors should watch next

TripSitter Clinic Ltd. (KETA.CN) plunged -88.78% to C$0.055 in market hours on 13 Feb 2026. KETA.CN stock saw a volume spike of 150,000 shares versus a 50-day average of 1,085, raising immediate liquidity and execution concerns. We assess why the drop happened, how the company’s fundamentals stack up, and what Meyka AI’s model projects for KETA.CN stock going forward.

KETA.CN stock: intraday snapshot and trading facts

TripSitter Clinic Ltd. (KETA.CN) traded on the CNQ exchange in Canada at C$0.055 on 13 Feb 2026. The stock opened at C$0.10, hit a high of C$0.10 and a low of C$0.055. Market cap stood at C$998,726.00 with 6,658,174 shares outstanding and relative volume of 1.38. The sharp move followed a previous close of C$0.49.

KETA.CN stock: likely drivers behind the steep decline

There is no material corporate press release in the public filings that explains the drop. Low liquidity and a large order flow can push small caps sharply lower, and KETA.CN stock shows those hallmarks today. The disconnect between the prior close of C$0.49 and the intraday low of C$0.055 points to concentrated selling or a block trade impact rather than a broad sector shock. For background market context see Investing.com market news.

KETA.CN stock: fundamentals and valuation

TripSitter Clinic Ltd. operates a telehealth ketamine platform and is listed in Healthcare. Latest reported EPS is -0.04 and trailing PE is -3.75, reflecting negative earnings. Book value per share is -0.1225 and enterprise value is C$1,387,234.00, indicating a thin equity cushion. Current ratio and cash per share metrics signal liquidity stress and a high debt-to-assets reading versus peer medians.

KETA.CN stock: technicals, liquidity and volatility risks

Technical indicators show extreme volatility: ADX 100.00 and RSI effectively 0.00, reflecting a one-sided move. Bollinger bands range shows a middle band near C$0.06 and an upper band at C$0.09. Average daily volume of 1,085 versus today’s 150,000 is a red flag for slippage and execution risk when trading KETA.CN stock.

KETA.CN stock: Meyka AI grade and forecast

Meyka AI rates KETA.CN with a score of 63.22 out of 100, Grade B, suggestion HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects C$0.35 monthly and C$0.10 quarterly targets. Versus the current C$0.055, that implies potential upside of 536.36% (monthly) and 81.82% (quarterly). Forecasts are model-based projections and not guarantees.

KETA.CN stock: outlook, catalysts and downside scenarios

Near-term scenarios split between a short squeeze recovery to C$0.10 and downside to the year low near C$0.025 if selling persists. Catalysts that could change direction include fresh capital raises, regulatory updates, or state-by-state expansion for telehealth services. Key risks remain weak liquidity, negative EPS, and high volatility in small-cap healthcare stocks.

Final Thoughts

KETA.CN stock plunged -88.78% to C$0.055 on 13 Feb 2026 amid extreme volume and no clear public catalyst. The move underscores liquidity risk in small-cap telehealth names and exposes shareholders to sharp execution losses. Meyka AI’s model shows a wide range of outcomes: a quarterly projection of C$0.10 implies +81.82% upside, while a monthly projection of C$0.35 implies +536.36%. Those figures reflect model scenarios, not guarantees. Investors should weigh fragile fundamentals — EPS -0.04, negative book value, and thin cash — against speculative upside. Use tight position sizing, confirm any corporate announcements, and monitor volume patterns before trading KETA.CN stock. Meyka AI provides this as AI-powered market analysis and not investment advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.